皮肤病靶向治疗专家共识（2025版）

doi:10.35541/cjd.20240054

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (2): 99-125.doi: 10.35541/cjd.20240054

皮肤病靶向治疗专家共识（2025版）

中国医学装备协会皮肤病与皮肤美容分会

中国医学装备协会皮肤病与皮肤美容分会

收稿日期:2024-01-26 修回日期:2024-10-21 发布日期:2025-02-07
通讯作者: 张学军 E-mail:ayzxj@vip.sina.com

Expert consensus on the treatment of dermatoses with targeted drugs （2025 version）

Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment

Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment

Received:2024-01-26 Revised:2024-10-21 Published:2025-02-07
Contact: Zhang Xuejun E-mail:ayzxj@vip.sina.com

摘要/Abstract

摘要： 【摘要】随着近年皮肤病学研究的发展，一些新型生物制剂及小分子靶向药物逐渐用于皮肤病治疗，显示出较好的疗效，尤其是在复杂及难治性皮肤病的治疗方面发挥了积极作用。如何将靶向治疗合理、有效、安全地用于皮肤病的治疗已经成为临床工作中备受关注的问题。为此，中国医学装备协会皮肤病与皮肤美容分会组织相关专家依据国内外研究数据和临床指南共识，结合中国皮肤病患者的特点，通过多次深入讨论和修改制订本共识，按照疾病分类，从生物制剂及小分子靶向药物的临床应用原则、治疗方案等方面为临床医生提供具体的指导意见。

关键词: 皮肤疾病, 治疗, 靶向药物, 生物制品, 化学制品, 专家共识

Abstract: 【Abstract】 With the progress in dermatology in recent decades, some new biologic agents and small-molecule targeted drugs have been approved for the treatment of skin diseases, and have showed favorable therapeutic effect, especially in the treatment of complex and refractory dermatoses. However, how to apply targeted therapy reasonably, effectively and safely in the treatment of skin diseases has become a matter of great concern in clinical practice. To this end, the Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment organized relevant experts to formulate this consensus through multiple in-depth discussions and revisions based on Chinese and international research data, clinical guidelines and consensus, as well as characteristics of Chinese patients. According to the classification of diseases, specific guidance was provided in this consensus for clinicians regarding the clinical application principles and treatment protocols of biologic agents and small-molecule targeted drugs.

Key words: Skin diseases, Therapy, Targeted drugs, Biologic products, Chemical agents, Expert consensus

中国医学装备协会皮肤病与皮肤美容分会. 皮肤病靶向治疗专家共识（2025版） [J]. 中华皮肤科杂志, 2025,58(2):99-125. doi:10.35541/cjd.20240054

Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Expert consensus on the treatment of dermatoses with targeted drugs （2025 version）[J]. Chinese Journal of Dermatology, 2025, 58(2): 99-125.doi:10.35541/cjd.20240054

参考文献 232

［1］	Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity［J］. Eur J Pharmacol, 2018,834:188⁃196. doi: 10.1016/j.ejphar.2018.07.034.
［2］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［3］	Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL⁃23 and IL⁃17 in the development of psoriasis⁃like lesions in a mouse model［J］. J Immunol, 2011,186（7）:4481⁃4489. doi: 10.4049/jimmunol.1000148.
［4］	Rendon A, Schäkel K. Psoriasis pathogenesis and treatment［J］. Int J Mol Sci, 2019,20（6）:1475. doi: 10.3390/ijms20061475.
［5］	Torres T, Filipe P. Small molecules in the treatment of psoriasis［J］. Drug Dev Res, 2015,76（5）:215⁃227. doi: 10.1002/ddr. 21263.
［6］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南（2024版）［J］. 中华皮肤科杂志, 2024,57（11）:976⁃997. doi: 10.35541/cjd.20240294.
［7］	Wang D, Chong VC, Chong WS, et al. A review on pityriasis rubra pilaris［J］. Am J Clin Dermatol, 2018,19（3）:377⁃390. doi: 10.1007/s40257⁃017⁃0338⁃1.
［8］	Naidoo A, Sibbald C, Fleming PJ, et al. Use of biologics in pityriasis rubra pilaris refractory to first⁃line systemic therapy: a systematic review ［Formula: see text］［J］. J Cutan Med Surg, 2020,24（1）:73⁃78. doi: 10.1177/1203475419887731.
［9］	Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1403⁃1414. doi: 10.1111/jdv.16464.
［10］	Boch K, Langan EA, Zillikens D, et al. Retrospective analysis of the clinical characteristics and patient⁃reported outcomes in vulval lichen planus: results from a single⁃center study［J］. J Dermatol, 2021,48（12）:1913⁃1917. doi: 10.1111/1346⁃8138. 16191.
［11］	Solimani F, Hilke FJ, Ghoreschi K. Pharmacology of Janus kinase inhibitors［J］. Hautarzt, 2019,70（12）:934⁃941. doi: 10.1007/s00105⁃019⁃04509⁃x.
［12］	Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases［J］. PLoS One, 2016,11（10）:e0164080. doi: 10.1371/journal.pone.0164080.
［13］	Di Lernia V. Targeting the IFN⁃γ/CXCL10 pathway in lichen planus［J］. Med Hypotheses, 2016,92:60⁃61. doi: 10.1016/j.mehy.2016.04.042.
［14］	Damsky W, Wang A, Olamiju B, et al. Treatment of severe lichen planus with the JAK inhibitor tofacitinib［J］. J Allergy Clin Immunol, 2020,145（6）:1708⁃1710.e2. doi: 10.1016/j.jaci.2020.01.031.
［15］	Seiringer P, Lauffer F, Pilz AC, et al. Tofacitinib in hypertrophic lichen planus［J］. Acta Derm Venereol, 2020,100（14）:adv00 220. doi: 10.2340/00015555⁃3585.
［16］	Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis［J］. JAMA Dermatol, 2021,157（3）:352⁃353. doi: 10.1001/jamadermatol.2020.4555.
［17］	Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series［J］. Dermatol Ther, 2018,31（6）:e12656. doi: 10.1111/dth.12656.
［18］	Lu R, Zeng X, Han Q, et al. Overexpression and selectively regulatory roles of IL⁃23/IL⁃17 axis in the lesions of oral lichen planus［J］. Mediators Inflamm, 2014,2014:701094. doi: 10.1155/2014/701094.
［19］	Gueiros LA, Arão T, Souza T, et al. IL17A polymorphism and elevated IL17A serum levels are associated with oral lichen planus［J］. Oral Dis, 2018,24（3）:377⁃383. doi: 10.1111/odi. 12718.
［20］	Hobo A, Harada K, Maeda T, et al. IL⁃17⁃positive mast cell infiltration in the lesional skin of lichen planopilaris: possible role of mast cells in inducing inflammation and dermal fibrosis in cicatricial alopecia［J］. Exp Dermatol, 2020,29（3）:273⁃277. doi: 10.1111/exd.13816.
［21］	Piccinni MP, Lombardelli L, Logiodice F, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus［J］. Oral Dis, 2014,20（2）:212⁃218. doi: 10.1111/odi.12094.
［22］	Shaker O, Hassan AS. Possible role of interleukin⁃17 in the pathogenesis of lichen planus［J］. Br J Dermatol, 2012,166（6）:1367⁃1368. doi: 10.1111/j.1365⁃2133.2011.10793.x.
［23］	Wang H, Han Q, Luo Z, et al. Oral lichen planus may enhance the expression of Th17⁃associated cytokines in local lesions of chronic periodontitis［J］. Clin Oral Investig, 2014,18（6）:1647⁃1654. doi: 10.1007/s00784⁃013⁃1131⁃z.
［24］	Ismail FF, Sinclair R. Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin⁃23/interleukin⁃17 pathway in the pathogenesis of lichen planus［J］. Australas J Dermatol, 2020,61（2）:e244⁃e245. doi: 10.1111/ajd.13183.
［25］	Solimani F, Pollmann R, Schmidt T, et al. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus［J］. Front Immunol, 2019,10:1808. doi: 10.3389/fimmu. 2019.01808.
［26］	Sil S, Shome S, Saha N, et al. Apremilast in oral lichen planus: report of two cases and review of literature［J］. Indian J Dermatol, 2023,68（6）:728. doi: 10.4103/ijd.ijd_499_23.
［27］	Goñi Esarte S, Arín Letamendía A, Vila Costas JJ,et al. Rituximab as rescue therapy in refractory esophageal lichen planus［J］. Gastroenterol Hepatol, 2013,36（4）:264⁃267. doi: 10.1016/j.gastrohep.2012.07.004.
［28］	Irla N, Schneiter T, Haneke E, et al. Nail lichen planus: successful treatment with etanercept［J］. Case Rep Dermatol, 2010,2（3）:173⁃176. doi: 10.1159/000321419.
［29］	王侠生, 廖康煌. 杨国亮皮肤病学［M］. 上海: 上海科学技术文献出版社, 2005.
［30］	赵辨. 中国临床皮肤病学［M］. 南京: 江苏科学技术出版社, 2010.
［31］	Duong TA, Valeyrie⁃Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs［J］. Lancet, 2017,390（10106）:1996⁃2011. doi: 10.1016/S0140⁃6736（16）30378⁃6.
［32］	中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识［J］. 中华皮肤科杂志, 2021,54（5）:376⁃381. doi: 10.35541/cjd.2020 1177.
［33］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 中国中重度特应性皮炎诊疗临床路径专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（11）:1000⁃1007. doi: 10.35541/cjd.20230247.
［34］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［35］	Zuberbier T, Asero R, Bindslev⁃Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria［J］. Allergy, 2009,64（10）:1427⁃1443. doi: 10.1111/j.1398⁃9995.2009.02178.x.
［36］	Bulkhi A, Cooke AJ, Casale TB. Biologics in chronic urticaria［J］. Immunol Allergy Clin North Am, 2017,37（1）:95⁃112. doi: 10.1016/j.iac.2016.08.004.
［37］	Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026.
［38］	Netchiporouk E, Nguyen CH, Thuraisingham T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series［J］. Pediatr Allergy Immunol, 2015,26（6）:585⁃588. doi: 10.1111/pai.12407.
［39］	中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识［J］. 中华皮肤科杂志, 2021,54（12）:1057⁃1062. doi: 10.35541/cjd.20210568.
［40］	Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo［J］. J Eur Acad Dermatol Venereol, 2018,32（7）:1059⁃1065. doi: 10.1111/jdv.14570.
［41］	Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management［J］. Dermatol Clin, 2018,36（3）:189⁃197. doi: 10. 1016/j.det.2018.02.003.
［42］	Leis M, Fleming P, Lynde CW. Prurigo nodularis: review and emerging treatments［J］. Skin Therapy Lett, 2021,26（3）:5⁃8.
［43］	Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management［J］. J Am Acad Dermatol, 2020,83（6）:1567⁃1575. doi: 10.1016/j.jaad.2020.04.182.
［44］	Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate⁃to⁃severe prurigo nodularis［J］. N Engl J Med, 2020,382（8）:706⁃716. doi: 10.1056/NEJMoa1908316.
［45］	Chen J, Li H, Zhu H. Successful treatment of chronic actinic dermatitis with dupilumab: a case report and review of the literature［J］. Clin Cosmet Investig Dermatol, 2021,14:1913⁃1917. doi: 10.2147/CCID.S342401.
［46］	Ali K, Wu L, Lou H, et al. Clearance of chronic actinic dermatitis with dupilumab therapy in Chinese patients: a case series［J］. Front Med （Lausanne）, 2022,9:803692. doi: 10.3389/fmed.2022.803692.
［47］	Patel N, Konda S, Lim HW. Dupilumab for the treatment of chronic actinic dermatitis［J］. Photodermatol Photoimmunol Photomed, 2020,36（5）:398⁃400. doi: 10.1111/phpp.12566.
［48］	陈国, 杨宝琦. 利妥昔单抗治疗自身免疫性大疱病的研究进展［J］. 实用皮肤病学杂志, 2019,12（2）:90⁃93.
［49］	Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases［J］. J Dermatol, 2015,42（1）:31⁃36. doi: 10. 1111/1346⁃8138.12711.
［50］	胥璟, 邓丹琪. 生物制剂治疗类天疱疮的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（5）:328⁃331. doi: 10.12144/zgmfskin 202105328.
［51］	Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology［J］. Br J Dermatol, 2015,172（4）:867⁃877. doi: 10.1111/bjd.13717.
［52］	Polansky M, Eisenstadt R, DeGrazia T, et al. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients［J］. J Am Acad Dermatol, 2019,81（1）:179⁃186. doi: 10.1016/j.jaad.2019.03.049.
［53］	Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases［J］. J Am Acad Dermatol, 2020,82（5）:1237⁃1239. doi: 10.1016/j.jaad.2019.11. 023.
［54］	Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid［J］. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549.
［55］	Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus［J］. Dermatol Online J, 2019,25（11）:13030/qt25q9w6r9 ［pii］.
［56］	Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad.2020.01.089.
［57］	Fairley JA, Baum CL, Brandt DS, et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab［J］. J Allergy Clin Immunol, 2009,123（3）:704⁃705. doi: 10.1016/j.jaci.2008.11.035.
［58］	James T, Salman S, Stevenson B, et al. IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid［J］. Clin Immunol, 2019,198:54⁃56. doi: 10.1016/j.clim.2018.12.015.
［59］	Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid［J］. J Am Acad Dermatol, 2014,71（3）:468⁃474. doi: 10.1016/j.jaad.2014.04.053.
［60］	Kushner CJ, Payne AS. Increasing the complement of therapeutic options in bullous pemphigoid［J］. J Invest Dermatol, 2018,138（2）:246⁃248. doi: 10.1016/j.jid.2017.09.026.
［61］	Iwata H, Vorobyev A, Koga H, et al. Meta⁃analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients［J］. Orphanet J Rare Dis, 2018,13（1）:153. doi: 10.1186/s13023⁃018⁃0896⁃1.
［62］	Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy［J］. J Dermatol, 2012,39（5）:477⁃479. doi: 10.1111/j.1346⁃8138.2011.01360.x.
［63］	Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab （anti⁃CD20 antibody） in the treatment of autoimmune bullous skin diseases［J］. J Dtsch Dermatol Ges, 2008,6（5）:366⁃373. doi: 10.1111/j.1610⁃0387.2007.06602.x.
［64］	Wu F, Gao J, Kang J, et al. B cells in rheumatoid arthritis：pathogenic mechanisms and treatment prospects［J］. Front Immunol, 2021,12:750753. doi: 10.3389/fimmu.2021.750753.
［65］	Kasperkiewicz M, Sadik CD, Bieber K, et al. Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options［J］. J Invest Dermatol, 2016,136（1）:24⁃33. doi: 10. 1038/JID.2015.356.
［66］	Maruta CW, Miyamoto D, Aoki V, et al. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview［J］. An Bras Dermatol, 2019,94（4）:388⁃398. doi: 10.1590/abd1806⁃4841.20199165.
［67］	Kwatra SG, Boozalis E, Pasieka H, et al. Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti⁃CD20 monoclonal antibodies［J］. Br J Dermatol, 2019,180（5）:1238⁃1239. doi: 10.1111/bjd.17577.
［68］	Zhang H, Hu B, Chen H, et al. Therapy of paraneoplastic pemphigus with rituximab: a case report［J］. Dermatol Ther, 2021,34（6）:e15144. doi: 10.1111/dth.15144.
［69］	Viswanath V, Tare D, Patil PC. Successful use of intravenous and intralesional rituximab in paraneoplastic pemphigus with Castleman's disease［J］. Int J Dermatol, 2021,60（9）:e352⁃e354. doi: 10.1111/ijd.15528.
［70］	Kuriyama K, Kitamura Y, Tsuji T, et al. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine［J］. Curr Probl Cancer, 2022,46（2）:100813. doi: 10.1016/j.currproblcancer.2021.100813.
［71］	耿研, 武丽君, 谢其冰, 等. 生物制剂在系统性红斑狼疮中应用的中国专家共识（2024版）［J］. 中华风湿病学杂志, 2024,28（2）:78⁃92. doi: 10.3760/cma.j.cn141217⁃20230711⁃00190⁃1.
［72］	Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus［J］. Ann Rheum Dis, 2019,78（6）:736⁃745. doi: 10.1136/annrheumdis⁃2019⁃215089.
［73］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［74］	Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis⁃associated interstitial lung disease: data from the SENSCIS trial［J］. Ann Rheum Dis, 2020, 79（11）:1478⁃1484. doi: 10.1136/annrheumdis⁃2020⁃217331.
［75］	Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti⁃IL⁃6 receptor antibody tocilizumab［J］. Rheumatology （Oxford）, 2010,49（12）:2408⁃12. doi: 10.1093/rheumatology/keq275.
［76］	Lilleker J, Murphy S, Cooper R. Selected aspects of the current management of myositis［J］. Ther Adv Musculoskelet Dis, 2016,8（4）:136⁃144. doi: 10.1177/1759720X16655126.
［77］	Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
［78］	Selva⁃O'Callaghan A, Pinal⁃Fernandez I, Trallero⁃Araguás E, et al. Classification and management of adult inflammatory myopathies［J］. Lancet Neurol, 2018,17（9）:816⁃828. doi: 10. 1016/S1474⁃4422（18）30254⁃0.
［79］	Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms （dryness of eyes or mouth, or both）［J］. Ann Rheum Dis, 1999,58（7）:423⁃427. doi: 10.1136/ard.58.7.423.
［80］	Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain［J］. Arthritis Care Res （Hoboken）, 2017,69（4）:517⁃527. doi: 10.1002/acr.22968.
［81］	刘佩玲, 赵金霞, 刘湘源. 干燥综合征治疗指南: 生物制剂的使用疲劳及炎性肌肉骨骼疼痛的治疗［J］. 中华风湿病学杂志, 2017,21（1）:67⁃70. doi: 10.3760/cma.j.issn.1007⁃7480.2017. 01.017.
［82］	Kim P, Grossman JM. Treatment of mixed connective tissue disease［J］. Rheum Dis Clin North Am, 2005,31（3）:549⁃565, viii. doi: 10.1016/j.rdc.2005.04.008.
［83］	Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease⁃associated interstitial lung disease （RECITAL）: study protocol for a randomised controlled trial［J］. Trials, 2017,18（1）:275. doi: 10.1186/s13063⁃017⁃2016⁃2.
［84］	Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease⁃associated interstitial lung disease in the UK （RECITAL）: a double⁃blind, double⁃dummy, randomised, controlled, phase 2b trial［J］. Lancet Respir Med, 2023,11（1）:45⁃54. doi: 10.1016/S2213⁃2600（22）00359⁃9.
［85］	Jiang B, Li T, Guo L, et al. Efficacy and safety of rituximab in systemic lupus erythematosus and Sjögren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases［J］. J Clin Rheumatol, 2015,21（5）:244⁃250. doi: 10.1097/RHU.0000000000000273.
［86］	Wang CY, Guo SH, Wang LP, et al. Clinical efficacy of low⁃dose rituximab on hematological abnormalities in patients with connective tissue disease［J］. Int J Clin Pharmacol Ther, 2019,57（10）:500⁃505. doi: 10.5414/CP203453.
［87］	Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult⁃onset Still's disease［J］. Clin Rev Allergy Immunol, 2020,58（1）:71⁃81. doi: 10.1007/s12016⁃019⁃08747⁃8.
［88］	Kedor C, Listing J, Zernicke J, et al. Canakinumab for treatment of adult⁃onset Still's disease to achieve reduction of arthritic manifestation （CONSIDER）: phase Ⅱ, randomised, double⁃blind, placebo⁃controlled, multicentre, investigator⁃initiated trial［J］. Ann Rheum Dis, 2020,79（8）:1090⁃1097. doi: 10.1136/
	annrheumdis⁃2020⁃217155.
［89］	Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still's disease: exposure⁃response analysis of pooled systemic juvenile idiopathic arthritis data by age groups［J］. Clin Exp Rheumatol, 2018,36（4）:668⁃675.
［90］	Vitale A, Berlengiero V, Sota J, et al. Real⁃life data on the efficacy of canakinumab in patients with adult⁃onset Still's disease［J］. Mediators Inflamm, 2020,2020:8054961. doi: 10. 1155/2020/8054961.
［91］	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012［J］. Int J Cancer, 2015,136（5）:E359⁃E386. doi: 10.1002/ijc.29210.
［92］	Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline update［J］. J Clin Oncol, 2018,36（4）:399⁃413. doi: 10.1200/JCO.2017.75.7724.
［93］	Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade［J］. Cancer, 2017,123（S11）:2143⁃2153. doi: 10.1002/cncr.30444.
［94］	Lee N, Zakka LR, Mihm MC Jr, et al. Tumour⁃infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy［J］. Pathology, 2016,48（2）:177⁃187. doi: 10.1016/j.pathol.2015. 12.006.
［95］	Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma［J］. J Surg Oncol, 2021,123（3）:782⁃788. doi: 10.1002/jso. 26229.
［96］	George DD, Armenio VA, Katz SC. Combinatorial immunotherapy for melanoma［J］. Cancer Gene Ther, 2017,24（3）:141⁃147. doi: 10.1038/cgt.2016.56.
［97］	Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer［J］. Nature, 2002,417（6892）:949⁃954. doi: 10.1038/nature00766.
［98］	Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432⁃case cohort［J］. Eur J Cancer, 2012,48（1）:94⁃100. doi: 10.1016/j.ejca.2011.06.056.
［99］	Larkin J, Chiarion⁃Sileni V, Gonzalez R, et al. Five⁃year survival with combined nivolumab and ipilimumab in advanced melanoma［J］. N Engl J Med, 2019,381（16）:1535⁃1546. doi: 10.1056/NEJMoa1910836.
［100］	Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma［J］. Lancet, 2021,398（10304）:1002⁃1014. doi: 10.1016/S0140⁃6736（21）01206⁃X.
［101］	Pires da Silva I, Lo S, Quek C, et al. Site⁃specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti⁃PD⁃1 therapy［J］. Cancer, 2020,126（1）:86⁃97. doi: 10.1002/cncr.32522.
［102］	D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis［J］. J Clin Oncol, 2017,35（2）:226⁃235. doi: 10.1200/JCO.2016.67.9258.
［103］	Nakamura Y, Namikawa K, Yoshino K, et al. Anti⁃PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients［J］. Ann Oncol, 2020,31（9）:1198⁃1206. doi: 10.1016/j.annonc.2020.05.031.
［104］	国家卫生健康委. 新型抗肿瘤药物临床应用指导原则（2023年版）［EB/OL］. ［2024⁃01⁃12］. https://www.gov.cn/zhengce/zhengceku/202401/P020240109528721822127.pdf.
［105］	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）黑色素瘤诊疗指南［M］. 北京: 人民卫生出版社, 2021.
［106］	Willemze R, Jaffe ES, Burg G, et al. WHO⁃EORTC classification for cutaneous lymphomas［J］. Blood, 2005,105（10）:3768⁃3785. doi: 10.1182/blood⁃2004⁃09⁃3502.
［107］	Wood GS, Wu J. Methotrexate and pralatrexate［J］. Dermatol Clin, 2015,33（4）:747⁃755. doi: 10.1016/j.det.2015.05.009.
［108］	Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T⁃cell lymphoma cells: relevance to mechanism of therapeutic action［J］. J Invest Dermatol, 2005,125（5）:1045⁃1052. doi: 10.1111/j.0022⁃202X.2005.23925.x.
［109］	Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T⁃cell lymphoma and relapsed peripheral T⁃cell lymphoma［J］. Clin Cancer Res, 2009,15（4）:1496⁃1503. doi: 10.1158/1078⁃0432.CCR⁃08⁃1215.
［110］	Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat （suberoylanilide hydroxamic acid, SAHA） for refractory cutaneous T⁃cell lymphoma （CTCL）［J］. Blood, 2007,109（1）:31⁃39. doi: 10.1182/blood⁃2006⁃06⁃025999.
［111］	O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies［J］. J Clin Oncol, 2006,24（1）:166⁃173. doi: 10.1200/JCO.2005.01.9679.
［112］	Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti⁃CD30 antibody⁃drug conjugate［J］. Am J Health Syst Pharm, 2013,70（7）:589⁃597. doi: 10.2146/ajhp110608.
［113］	Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab［J］. Eur J Haematol, 2003,71（4）:250⁃256. doi: 10.1034/j.1600⁃0609.2003.00143.x.
［114］	Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T⁃cell lymphoma （mycosis fungoides and Sézary syndrome）: part Ⅰ. Diagnosis: clinical and histopathologic features and new molecular and biologic markers［J］. J Am Acad Dermatol, 2014,70（2）:205.e1⁃e16; quiz 221⁃222. doi: 10.1016/j.jaad.2013.07. 049.
［115］	Watson S, Marx JB. Mogamulizumab⁃kpkc: a novel therapy for the treatment of cutaneous T⁃cell lymphoma［J］. J Adv Pract Oncol, 2019,10（8）:883⁃888. doi: 10.6004/jadpro.2019.10.8.10.
［116］	Duvic M, Pinter⁃Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti⁃CCR4 antibody, in previously treated patients with cutaneous T⁃cell lymphoma［J］. Blood, 2015,125（12）:1883⁃1889. doi: 10.1182/blood⁃2014⁃09⁃600924.
［117］	Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well⁃tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T⁃cell lymphoma［J］. Blood, 2012,119（18）:4115⁃4122. doi: 10.1182/blood⁃2011⁃11⁃390211.
［118］	Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T⁃cell lymphoma［J］. J Clin Oncol, 2010,28（29）:4485⁃4491. doi: 10.1200/JCO.2010.28.9066.
［119］	Kim YH, Tavallaee M, Sundram U, et al. PhaseⅡ investigator⁃initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi⁃institution collaborative project［J］. J Clin Oncol, 2015,33（32）:3750⁃3758. doi: 10.1200/JCO.2014.60.3969.
［120］	Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab （anti⁃CD52 monoclonal antibody） in patients with advanced mycosis fungoides/Sezary syndrome［J］. Blood, 2003,101（11）:4267⁃4272. doi: 10.1182/blood⁃2002⁃09⁃2802.
［121］	Nagarajan P, Asgari MM, Green AC, et al. Keratinocyte carcinomas: current concepts and future research priorities［J］. Clin Cancer Res, 2019,25（8）:2379⁃2391. doi: 10.1158/1078⁃0432.CCR⁃18⁃1122.
［122］	中华医学会皮肤性病学分会皮肤肿瘤研究中心, 中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤鳞状细胞癌诊疗专家共识（2021）［J］. 中华皮肤科杂志, 2021,54（8）:653⁃664. doi: 10.35541/cjd.20201140.
［123］	Aboul⁃Fettouh N, Morse D, Patel J, et al. Immunotherapy and systemic treatment of cutaneous squamous cell carcinoma［J］. Dermatol Pract Concept, 2021,11（Suppl 2）:e2021169S. doi: 10.5826/dpc.11S2a169S.
［124］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment［J］. Eur J Cancer, 2020,128:83⁃102. doi: 10.1016/j.ejca.2020.01.008.
［125］	Grob JJ, Gonzalez R, Basset⁃Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single⁃arm phaseⅡ trial （KEYNOTE⁃629）［J］. J Clin Oncol, 2020,38（25）:2916⁃2925. doi: 10.1200/JCO. 19.03054.
［126］	Migden MR, Khushalani NI, Chang A, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open⁃label, phase 2, single⁃arm trial［J］. Lancet Oncol, 2020,21（2）:294⁃305. doi: 10.1016/S1470⁃2045（19）30728⁃4.
［127］	Maubec E, Boubaya M, Petrow P, et al. PhaseⅡ study of pembrolizumab as first⁃line, single⁃drug therapy for patients with unresectable cutaneous squamous cell carcinomas［J］. J Clin Oncol, 2020,38（26）:3051⁃3061. doi: 10.1200/JCO.19. 03357.
［128］	Ogata D, Tsuchida T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma［J］. Curr Treat Options Oncol, 2019,20（4）:30. doi: 10.1007/s11864⁃019⁃0629⁃2.
［129］	Argenziano G, Fargnoli MC, Fantini F, et al. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion［J］. Ther Adv Med Oncol, 2022,14:175883 5921106 6272. doi: 10.1177/17588359211066272.
［130］	Lebas E, Marchal N, Rorive A, et al. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel［J］. Expert Rev Anticancer Ther, 2021,21（4）:355⁃363. doi: 10.1080/14737140.2021.1876567.
［131］	Fisher J, Zeitouni N, Fan W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient⁃centered systematic review［J］. J Am Acad Dermatol, 2020,82（6）:1490⁃1500. doi: 10.1016/j.jaad.2019.07.005.
［132］	Ridd K, Bastian BC. Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma［J］. J Invest Dermatol, 2010,130（3）:901⁃903. doi: 10.1038/jid.2009.312.
［133］	中华医学会皮肤性病学分会皮肤肿瘤研究中心, 中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤基底细胞癌诊疗专家共识（2021）［J］. 中华皮肤科杂志, 2021,54（9）:757⁃764. doi: 10.35541/cjd.20201139.
［134］	Wahid M, Jawed A, Mandal RK, et al. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas［J］. Crit Rev Oncol Hematol, 2016,98:235⁃241. doi: 10.1016/j.critrevonc. 2015.11.006.
［135］	Casey D, Demko S, Shord S, et al. FDA approval summary: sonidegib for locally advanced basal cell carcinoma［J］. Clin Cancer Res, 2017,23（10）:2377⁃2381. doi: 10.1158/1078⁃0432.CCR⁃16⁃2051.
［136］	Meiss F, Andrlová H, Zeiser R. Vismodegib［J］. Recent Results Cancer Res, 2018,211:125⁃139. doi: 10.1007/978⁃3⁃319⁃91442⁃8_9.
［137］	Fazaa A, Makhlouf Y, Ben Massoud F, et al. Behcet disease: epidemiology, classification criteria and treatment modalities ［J］. Expert Rev Clin Immunol, 2024, 20（12）: 1437⁃1448.doi: 10.1080/1744666X.2024.2388693.
［138］	Hatemi G, Christensen R, Bang D, et al. 2018 Update of the EULAR recommendations for the management of Behçet's syndrome［J］. Ann Rheum Dis, 2018,77（6）:808⁃818. doi: 10. 1136/annrheumdis⁃2018⁃213225.
［139］	Lin S, Xu Z, Lin Z, et al. Advances in pathogenesis and treatment of ocular involvement in Behcet's disease［J］. Front Immunol, 2023,14:1206959. doi: 10.3389/fimmu.2023.1206959.
［140］	嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识编写组. 嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识［J］. 中华结核和呼吸杂志, 2018,41（7）:514⁃521. doi: 10.3760/cma.j.issn.1001⁃0939.2018.07.002.
［141］	Pons⁃Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature［J］. Autoimmun Rev, 2011,10（11）:679⁃684. doi: 10.1016/j.autrev.2011.04.028.
［142］	Seeliger B, Förster M, Happe J, et al. Interferon⁃α for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: a single⁃center retrospective observational cohort study［J］. J Rheumatol, 2017,44（6）:806⁃814. doi: 10. 3899/jrheum.160907.
［143］	Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review［J］. Autoimmun Rev, 2021,20（2）:102737. doi: 10.1016/j.autrev.2020.102737.
［144］	Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36⁃month follow⁃up study［J］. J Asthma, 2016,53（2）:201⁃206. doi: 10.3109/02770903.2015.1081700.
［145］	Lazarewicz K, Watson P. Giant cell arteritis［J］. BMJ, 2019,365:l1964. doi: 10.1136/bmj.l1964.
［146］	Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis［J］. Ann Rheum Dis, 2020,79（1）:19⁃30. doi: 10. 1136/annrheumdis⁃2019⁃215672.
［147］	Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis［J］. Arthritis Rheumatol, 2021,73（8）:1349⁃1365. doi: 10.1002/art. 41774.
［148］	Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant⁃cell arteritis［J］. N Engl J Med, 2017,377（4）:317⁃328. doi: 10.1056/NEJMoa1613849.
［149］	Cid MC, Ríos⁃Garcés R, Terrades⁃García N, et al. Treatment of giant⁃cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies［J］. Rheumatology （Oxford）, 2020,59（Suppl 3）:iii17⁃iii27. doi: 10.1093/rheumatology/kez645.
［150］	Kitching AR, Anders HJ, Basu N, et al. ANCA⁃associated vasculitis［J］. Nat Rev Dis Primers, 2020,6（1）:71. doi: 10.1038/s41572⁃020⁃0204⁃y.
［151］	Nozaki Y. New insights into novel therapeutic targets in ANCA⁃associated vasculitis［J］. Front Immunol, 2021,12:631055. doi: 10.3389/fimmu.2021.631055.
［152］	Lee A. Avacopan: first approval［J］. Drugs, 2022,82（1）:79⁃85. doi: 10.1007/s40265⁃021⁃01643⁃6.
［153］	Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum［J］. Expert Rev Clin Pharmacol, 2020,13（2）:157⁃161. doi: 10.1080/17512433.2020.1709825.
［154］	Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial［J］. Gut, 2006,55（4）:505⁃509. doi: 10.1136/gut.2005.074815.
［155］	Yamasaki K, Yamanaka K, Zhao Y, et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty⁃six⁃week phase 3 open⁃label study［J］. J Dermatol, 2020,47（12）:1383⁃1390. doi: 10.1111/1346⁃8138.15533.
［156］	Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series［J］. Int J Dermatol, 2007,46（10）:1095⁃1099. doi: 10.1111/j.1365⁃4632.2007.03286.x.
［157］	Hurabielle C, Schneider P, Baudry C, et al. Certolizumab pegol⁃ a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease［J］. J Dermatolog Treat, 2016,27（1）:67⁃69. doi: 10.3109/09546634.2015.1034075.
［158］	Diotallevi F, Campanati A, Radi G, et al. Pyoderma gangrenosum successfully treated with golimumab: case report and review of the literature［J］. Dermatol Ther, 2019,32（4）:e12928. doi: 10.1111/dth.12928.
［159］	Westerdahl JS, Nusbaum KB, Chung CG, et al. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes［J］. J Dermatolog Treat, 2022,33（4）:2386⁃2390. doi: 10.1080/09546634.2021.1937475.
［160］	Reese AM, Erickson K, Reed KB, et al. Modified dose of guselkumab for treatment of pyoderma gangrenosum［J］. JAAD Case Rep, 2022,21:38⁃42. doi: 10.1016/j.jdcr.2021.11.030.
［161］	Burgdorf B, Schlott S, Ivanov IH, et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab［J］. Int Wound J, 2020,17（4）:1086⁃1088. doi: 10.1111/iwj.13359.
［162］	Kok Y, Nicolopoulos J, Varigos G, et al. Tildrakizumab in the treatment of PASH syndrome: a potential novel therapeutic target［J］. Australas J Dermatol, 2020,61（3）:e373⁃e374. doi: 10.1111/ajd.13285.
［163］	McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20940430. doi: 10.1177/2050313X20940430.
［164］	Kao AS, King AD, Daveluy S. Successful treatment of cabozantinib⁃induced pyoderma gangrenosum with ixekizumab therapy: a case report［J］. Dermatol Ther, 2022,35（9）:e15716. doi: 10.1111/dth.15716.
［165］	Tee MW, Avarbock AB, Ungar J, et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy［J］. JAAD Case Rep, 2020,6（11）:1167⁃1169. doi: 10.1016/j.jdcr.2020.08. 033.
［166］	Acquitter M, Plantin P, Kupfer I, et al. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report［J］. Ann Intern Med, 2015,163（1）:70⁃71. doi: 10.7326/L15⁃5107.
［167］	Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid⁃refractory pyoderma gangrenosum［J］. Br J Dermatol, 2015,173（5）:1216⁃1223. doi: 10.1111/bjd.14037.
［168］	Lu JD, Milakovic M, Ortega⁃Loayza AG, et al. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX⁃1［J］. Expert Opin Investig Drugs, 2020,29（11）:1179⁃1185. doi: 10.1080/13543784.2020.1819981.
［169］	Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum［J］. Clin Exp Dermatol, 2021,46（6）:1082⁃1085. doi: 10.1111/ced.14683.
［170］	Scheinberg M, Machado LA, M Castro LG, et al. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor［J］. J Transl Autoimmun, 2021,4:100099. doi: 10.1016/j.jtauto.2021.100099.
［171］	Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor［J］. Br J Dermatol, 2018,179（2）:504⁃505. doi: 10.1111/bjd.16468.
［172］	Cohen PR. Sweet's syndrome⁃⁃a comprehensive review of an acute febrile neutrophilic dermatosis［J］. Orphanet J Rare Dis, 2007,2:34. doi: 10.1186/1750⁃1172⁃2⁃34.
［173］	Mollaeian A, Roudsari H, Talebi E. Sweet's syndrome: a classical presentation of a rare disease［J］. J Investig Med High Impact Case Rep, 2019,7:23247096 19895164. doi: 10. 1177/2324709619895164.
［174］	von den Driesch P. Sweet's syndrome （acute febrile neutrophilic dermatosis）［J］. J Am Acad Dermatol, 1994,31（4）:535⁃556; quiz 557⁃560. doi: 10.1016/s0190⁃9622（94）70215⁃2.
［175］	Ambrose NL, Tobin AM, Howard D. Etanercept treatment in Sweet's syndrome with inflammatory arthritis［J］. J Rheumatol, 2009,36（6）:1348⁃1349. doi: 10.3899/jrheum.080698.
［176］	Watson IT, Haugh I, Gardner AR, et al. Histiocytoid Sweet syndrome successfully treated with etanercept［J］. Proc （Bayl Univ Med Cent）, 2018,31（3）:347⁃349. doi: 10.1080/08998280. 2018.1460132.
［177］	Agarwal A, Barrow W, Selim MA, et al. Refractory subcutaneous Sweet syndrome treated with adalimumab［J］. JAMA Dermatol, 2016,152（7）:842⁃844. doi: 10.1001/jamadermatol.2016.0503.
［178］	Calabrese L, Caldarola G, Peris K, et al. Recalcitrant Sweet syndrome successfully treated with adalimumab［J］. J Dtsch Dermatol Ges, 2021,19（1）:122⁃124. doi: 10.1111/ddg.14223.
［179］	Foster EN, Nguyen KK, Sheikh RA, et al. Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab［J］. Clin Dev Immunol, 2005,12（2）:145⁃149. doi: 10.1080/17402520500134254.
［180］	Castro⁃Fernández M, Sánchez⁃Muñoz D, Ruíz⁃Granados E, et al. Coexistence of pyoderma gangrenosum and Sweet's syndrome in a patient with ulcerative colitis［J］. Am J Gastroenterol, 2007,102（12）:2865⁃2866. doi: 10.1111/j.1572⁃0241.2007.01528_8.x.
［181］	Kluger N, Gil⁃Bistes D, Guillot B, et al. Efficacy of anti⁃interleukin⁃1 receptor antagonist anakinra （Kineret®） in a case of refractory Sweet's syndrome［J］. Dermatology, 2011,222（2）:123⁃127. doi: 10.1159/000326112.
［182］	Seminario⁃Vidal L, Guerrero C, Sami N. Refractory Sweet's syndrome successfully treated with rituximab［J］. JAAD Case Rep, 2015,1（3）:123⁃125. doi: 10.1016/j.jdcr.2015.03.002.
［183］	Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides［J］. Arthritis Rheum, 2013,65（1）:1⁃11. doi: 10.1002/art.37715.
［184］	王慧杰, 秦蕾, 武森森, 等. 结节性多动脉炎治疗进展［J］. 世界临床药物, 2021,42（6）:433⁃437. doi: 10.13683/j.wph.2021. 06.002.
［185］	Velasco N, Karki S, Tenreiro OR. Successful treatments of polyarteritis nodosa cerebral vasculitis and recurrent Elizabethkingia meningoseptica septicaemia in a dialysis patient［J］. BMJ Case Rep, 2019,12（11）:e231478. doi: 10.1136/bcr⁃2019⁃231478.
［186］	Schnappauf O, Zhou Q, Moura NS, et al. Deficiency of adenosine deaminase 2 （DADA2）: hidden variants, reduced penetrance, and unusual inheritance［J］. J Clin Immunol, 2020,40（6）:917⁃926. doi: 10.1007/s10875⁃020⁃00817⁃3.
［187］	Ginsberg S, Rosner I, Slobodin G, et al. Infliximab for the treatment of refractory polyarteritis nodosa［J］. Clin Rheumatol, 2019,38（10）:2825⁃2833. doi: 10.1007/s10067⁃019⁃04474⁃9.
［188］	Ostrovršnik J, Hočevar A, Lestan B, et al. Long⁃term follow⁃up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa［J］. Amyloid, 2016,23（4）:260⁃261. doi: 10.1080/13506129.2016.1232648.
［189］	Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference［J］. Arthritis Rheum, 1994,37（2）:187⁃192. doi: 10.1002/art.1780370206.
［190］	Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta⁃analyses of clinical trials in idiopathic pulmonary fibrosis［J］. Lancet Respir Med, 2017,5（1）:33⁃41. doi: 10.1016/S2213⁃2600（16）30326⁃5.
［191］	Abe Y, Yamaji K, Endo Y, et al. Plasma exchange therapy to reduce mortality in Japanese patients with diffuse alveolar hemorrhage and microscopic polyangiitis［J］. Ther Apher Dial, 2020,24（2）:208⁃214. doi: 10.1111/1744⁃9987.12939.
［192］	Thiel J, Troilo A, Salzer U, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36⁃month follow⁃up analysis［J］. J Allergy Clin Immunol Pract, 2017,5（6）:1556⁃1563. doi: 10.1016/j.jaip.2017.07.027.
［193］	Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA⁃associated vasculitis［J］. N Engl J Med, 2010,363（3）:221⁃232. doi: 10.1056/NEJMoa0909905.
［194］	Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group （FVSG） for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody⁃associated necrotizing vasculitides［J］. Presse Med, 2013,42（10）:1317⁃1330. doi: 10. 1016/j.lpm.2013.08.003.
［195］	Sakai R, Kondo T, Kikuchi J, et al. Corticosteroid⁃free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single⁃arm, single⁃center, clinical trial［J］. Mod Rheumatol, 2016,26（6）:900⁃907. doi: 10.3109/14397595.2016.1160968.
［196］	Torosoff M, Breen T, Balulad S, et al. Resolution of sinus bradycardia, high⁃grade heart block, and left ventricular systolic dysfunction with rituximab therapy in Henoch⁃Schonlein purpura［J］. Intern Med J, 2018,48（7）:868⁃871. doi: 10.1111/imj.13948.
［197］	Pindi Sala T, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent Henoch⁃Schönlein purpura adult with rituximab［J］. Case Rep Med, 2014,2014:619218. doi: 10.1155/2014/619218.
［198］	Oshima Y, Hoshino J, Suwabe T, et al. Multicentric Castleman's disease associated with IgA vasculitis （Henoch⁃Schönlein purpura） responding well to tocilizumab: a case report［J］. Clin Rheumatol, 2017,36（3）:729⁃733. doi: 10.1007/s10067⁃017⁃3568⁃y.
［199］	Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus⁃infected patients［J］. Autoimmun Rev, 2011,10（8）:444⁃454. doi: 10.1016/j.autrev.2011.01.008.
［200］	Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV⁃related cryoglobulinemic vasculitis: long⁃term follow up data of a randomized controlled multicentre study［J］. J Autoimmun, 2015,63:88⁃93. doi: 10.1016/j.jaut.2015.07.012.
［201］	Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis［J］. Br J Dermatol, 2000,143（6）:1324. doi: 10.1046/j.1365⁃2133.2000.03913.x.
［202］	Eiser AR, Singh P, Shanies HM. Sustained dapsone⁃induced remission of hypocomplementemic urticarial vasculitis⁃⁃a case report［J］. Angiology, 1997,48（11）:1019⁃1022. doi: 10.1177/000331979704801114.
［203］	Jachiet M, Flageul B, Deroux A, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty⁃seven patients［J］. Arthritis Rheumatol, 2015,67（2）:527⁃534. doi: 10.1002/art.38956.
［204］	中国中西医结合学会皮肤性病专业委员会色素病学组, 中华医学会皮肤性病学分会白癜风研究中心, 中国医师协会皮肤科医师分会色素病专委会, 等. 白癜风诊疗共识（2024版）［J］. 中华皮肤科杂志, 2024,57（12）:1065⁃1070. doi: 10.35541/cjd.20240260.
［205］	Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021［J］. Br J Dermatol, 2022,186（1）:18⁃29. doi: 10.1111/bjd.20596.
［206］	Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial［J］. Lancet, 2020,396（10244）:110⁃120. doi: 10.1016/S0140⁃6736（20）30609⁃7.
［207］	Janssen JC, Mulder E, van der Veldt AAM. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo ［J］. N Engl J Med, 2023, 388（3）: 283. doi: 10.1056/NEJMc221 5181.
［208］	Song H, Hu Z, Zhang S, et al. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real⁃world clinical practice［J］. Dermatol Ther, 2022,35（11）:e15821. doi: 10.1111/dth.15821.
［209］	Mobasher P, Guerra R, Li SJ, et al. Open⁃label pilot study of tofacitinib 2% for the treatment of refractory vitiligo［J］. Br J Dermatol, 2020,182（4）:1047⁃1049. doi: 10.1111/bjd.18606.
［210］	Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV⁃B phototherapy for the treatment of vitiligo: a randomized multicenter trial［J］. JAMA Dermatol, 2015,151（1）:42⁃50. doi: 10.1001/jamadermatol.2014.1875.
［211］	Toh J, Chuah SY, Jhingan A, et al. Afamelanotide implants and narrow⁃band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians［J］. J Am Acad Dermatol, 2020,82（6）:1517⁃1519. doi: 10.1016/j.jaad.2020.01.035.
［212］	You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases［J］. Clin Rev Allergy Immunol, 2020,59（3）:334⁃351. doi: 10.1007/s12016⁃020⁃08786⁃6.
［213］	Kobal I, Ramot Y. Janus kinase inhibitors for the treatment of alopecia areata［J］. Hautarzt, 2022,73（5）:336⁃343. doi: 10. 1007/s00105⁃022⁃04982⁃x.
［214］	Gouya L, Martin⁃Schmitt C, Robreau AM, et al. Contribution of a common single⁃nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria［J］. Am J Hum Genet, 2006,78（1）:2⁃14. doi: 10.1086/498620.
［215］	Collins P, Ferguson J. Narrow⁃band UVB （TL⁃01） phototherapy: an effective preventative treatment for the photodermatoses［J］. Br J Dermatol, 1995,132（6）:956⁃963. doi: 10.1111/j.1365⁃2133.1995.tb16955.x.
［216］	Warren LJ, George S. Erythropoietic protoporphyria treated with narrow⁃band （TL⁃01） UVB phototherapy［J］. Australas J Dermatol, 1998,39（3）:179⁃182. doi: 10.1111/j.1440⁃0960. 1998.tb01278.x.
［217］	Wensink D, Wagenmakers M, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria［J］. Expert Rev Clin Pharmacol, 2021,14（2）:151⁃160. doi: 10.1080/17512433.2021.1879638.
［218］	Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1［J］. J Med Genet, 2002,39（5）:311⁃314. doi: 10.1136/jmg.39.5.311.
［219］	Reilly KM, Kim A, Blakely J, et al. Neurofibromatosis type 1⁃associated MPNST state of the science: outlining a research agenda for the future［J］. J Natl Cancer Inst, 2017,109（8）:djx124. doi: 10.1093/jnci/djx124.
［220］	Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors［J］. Oncologist, 2014,19（2）:193⁃201. doi: 10.1634/theoncologist.2013⁃0328.
［221］	Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1⁃related plexiform neurofibromas［J］. N Engl J Med, 2016,375（26）:2550⁃2560. doi: 10.1056/NEJMoa1605943.
［222］	Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas［J］. N Engl J Med, 2020,382（15）:1430⁃1442. doi: 10.1056/NEJMoa1912735.
［223］	Wang Y, Marier JF, Kassir N, et al. Pharmacokinetics, pharmacodynamics, and exposure⁃response of lanadelumab for hereditary angioedema［J］. Clin Transl Sci, 2020,13（6）:1208⁃1216. doi: 10.1111/cts.12806.
［224］	Zuraw BL. Clinical practice. Hereditary angioedema［J］. N Engl J Med, 2008,359（10）:1027⁃1036. doi: 10.1056/NEJMcp0803977.
［225］	Gupta R, Balduzzi J, Davis⁃Lorton M. C1⁃esterase inhibitor （Cinryze®） use in the treatment of pediatric hereditary angioedema［J］. Immunotherapy, 2018,10（8）:635⁃642. doi: 10.2217/imt⁃2017⁃0049.
［226］	Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database［J］. Pharmacotherapy, 2012,32（10）:902⁃909. doi: 10.1002/j.1875⁃9114.2012.01126.
［227］	Zuraw BL, Christiansen SC. New promise and hope for treating hereditary angioedema［J］. Expert Opin Investig Drugs, 2008,17（5）:697⁃706. doi: 10.1517/13543784.17.5.697.
［228］	Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody［J］. J Biol Chem, 2014,289（34）:23596⁃23608. doi: 10.1074/jbc.M114.569061.
［229］	Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency［J］. J Allergy Clin Immunol Pract, 2013,1（5）:458⁃467. doi: 10.1016/j.jaip.2013.07.002.
［230］	Wang B, Yang W, Wen W, et al. Gamma⁃secretase gene mutations in familial acne inversa［J］. Science, 2010,330（6007）:1065. doi: 10.1126/science.1196284.
［231］	Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:619⁃644. doi: 10.1111/jdv.12966.
［232］	Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa［J］. N Engl J Med, 2016,375（5）:422⁃434. doi: 10.1056/NEJMoa1504370.

[1]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881.
[2]	袁勇勇潘萌. 家族性慢性良性天疱疮研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240182-e20240182.
[3]	叶慧邓仕琳梁景耀张锡宝. 特应性皮炎复发控制与组织驻留记忆性T细胞的相关性研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240192-e20240192.
[4]	李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240247-e20240247.
[5]	董艺穆妮热·塔伊尔闫昕章星琪. 机器学习在皮肤疾病中的研究应用[J]. 中华皮肤科杂志, 2025, 0(3): 20240290-e20240290.
[6]	魏亚鹿沈征宇. 空间转录组学及其在皮肤疾病中的应用[J]. 中华皮肤科杂志, 2025, 0(3): 20220429-e20220429.
[7]	李美荣唐旭华吴榕刘文韬冯佩英. 国内少见的双间新柱顶孢致皮肤感染4例[J]. 中华皮肤科杂志, 2025, 0(2): 20230579-e20230579.
[8]	郭伟楠王俊霞陈慧郝军峰李冰卫静宜赵涛. 自体脂肪干细胞胶填充治疗凹陷性痤疮瘢痕疗效观察[J]. 中华皮肤科杂志, 2025, 58(2): 167-169.
[9]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风疗效及安全性的单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 0(2): 20240421-e20240421.
[10]	中国中西医结合学会皮肤性病专业委员会中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. 常见非黑素细胞性皮肤肿瘤的反射式共聚焦显微镜特征专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 20-33.
[11]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会老年皮肤病学组. [开放获取] 老年皮肤瘙痒症诊疗与康复专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 1-8.
[12]	中国康复医学会皮肤病康复专业委员会中国康复医学会光动力治疗与康复专业委员会中华医学会皮肤性病学分会光动力治疗协作组. [开放获取] 氨基酮戊酸光动力疗法治疗非黑色素瘤皮肤癌临床应用专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(1): 9-19.
[13]	廖彩荷王佩茹吴明顺孙晓飞张国龙王秀丽. 联合氨基酮戊酸光动力疗法治疗老年颜面部基底细胞癌的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 34-39.
[14]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[15]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.

皮肤病靶向治疗专家共识（2025版）

Expert consensus on the treatment of dermatoses with targeted drugs （2025 version）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 232

相关文章 15

Metrics

本文评价

推荐阅读 10